News and Trends 25 Nov 2016 Structural Biology meets Drug Discovery in this Cool Company After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech. City: Munich, Germany Founded: 1999 Employees: 80+ Financial data: The company just announced a €157M ($167M) deal with MSD Mission: Proteros’ expertise in structural biology […] November 25, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2016 Stories We Didn’t Cover: Malaria Vaccine Money, Diabetes FDA Approvals Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. WHO has injected €14M into GSK to advance its malaria vaccine. Umecrine Cognition, a […] November 25, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2016 A Finnish Company opens a New Avenue to Alternative Protein How do you solve a problem like the viability of small-scale biogas production? Protein feed with a side of bioplastic, according to the Technical Research Centre of Finland. This emission-reducing process could not only yield interesting biobased products, but also solve some self-sufficiency and food security problems for Europe. Biogas is a promising biofuel, as it […] November 24, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2016 Infographic: The Changing Face of UK Drug Discovery by the Numbers After Brexit, UK pharma is striving to reinvigorate drug discovery through collaboration. This infographic shows why that’s necessary. A new report from the Association of the British Pharmaceutical Industry (ABPI) has a grim finding: the UK is beginning to lose out on global drug discovery investment compared to 10 years ago. Spending on pharmaceutical R&D […] November 24, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2016 This Company joins a Tech Initiative to Repair the Heart with Stem Cells Eppendorf joins a Horizon 2020 consortium to support bioreactor development for stem cell cultivation for heart attack patients. Stem cells have huge potential to treat or even cure a wide variety of medical conditions. Efforts to mitigate damage after a heart attack with stem cells are making a lot of progress. Researchers have successfully grown […] November 23, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2016 These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’ GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […] November 23, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024? Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Sanofi quietly leaves Bladder Cancer Patients in the lurch Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 One Antibody to Neutralize 98% of All HIV Strains: Closer to a Cure? A new hope for HIV: a single antibody that can target nearly all viral strains at once. What does it mean for the search of a global cure? Last week, a research article in Cell Immunity reported a detailed study of an antibody that could neutralize 98% of HIV strains. The N6 antibody can also […] November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 Celyad’s Autologous CAR-T Therapy enters Phase Ib Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […] November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 “We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease” Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […] November 21, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2016 Looking for outperforming cell lines ? CHOvolution is an all-in-one kit for GMP Bioproduction For any drug developer or service provider, cell line development is one of the most challenging phases, especially when subsequent GMP compliance is required. The need to secure good cell lines can, therefore, make all the difference in getting any biological to the market. The Swiss company Celonic has produced CHOvolution™, a cell line kit that allows you to […] November 19, 2016 - 4 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email